Sequencing BTK inhibitor therapy in CLL: treatment considerations and emerging strategies

June 30, 2026 11:13am 19 min

This podcast explores sequencing strategies and treatment considerations for BTK inhibitors in chronic lymphocytic leukemia (CLL). Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses treatment op...

Precision medicine in AML: from targeted therapy to transplantation

June 22, 2026 11:43am 19 min

This podcast explores the evolving role of precision medicine in acute myeloid leukemia (AML), highlighting advances in molecular profiling, targeted therapies, measurable residual disease (MRD) assessment, and transplan...

MPNs in focus: disease progression, risk assessment, and emerging treatments

June 15, 2026 11:58am 20 min

This VJHemOnc podcast explores how advances in disease biology, risk stratification, and therapeutic development are reshaping the management of myeloproliferative neoplasms (MPNs). Stephen Oh, MD, PhD, Washington Univer...

The evolving role of cellular therapies and T-cell engagers in lymphoma

May 29, 2026 9:59am 19 min

This VJHemOnc podcast explores emerging cellular therapies and T-cell engagers in non-Hodgkin lymphoma (NHL). Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, is joined by Paolo Strati, MD, The University...

Multiple myeloma in 2026: MRD, BCMA therapies, CAR-T, and the path to cure

May 22, 2026 10:53am 20 min

This VJHemOnc podcast explores how evolving treatment strategies, immunotherapies, and MRD-driven approaches are reshaping the management of multiple myeloma and precursor disease. Irene Ghobrial, MD, Dana-Farber Cancer ...

Dual-targeting CAR T-cell therapies in LBCL: efficacy, safety, and bridging therapy

May 15, 2026 8:43am 25 min

This VJHemOnc podcast features a roundtable discussion from the 8th International Workshop on CAR-T and Bispecifics (iwCAR-T) 2026 on the evolving role of dual-targeting CAR T-cell therapies in large B-cell lymphoma (LBC...

Advances in gene-based therapies for SCD and thalassemia: access, outcomes & innovation

May 08, 2026 8:11am 17 min

This VJHemOnc podcast explores the latest advances in gene-based therapies for sickle cell disease (SCD) and thalassemia, highlighting progress in patient access, selection, treatment delivery, and clinical outcomes. Sun...

The evolving role of BTK inhibitors in CLL

May 01, 2026 5:04am 25 min

Adverse events in the post-CAR T-cell therapy setting: infections, less common toxicities, and advice for physicians

April 24, 2026 3:58am 19 min

In this episode of the podcast, we focus on adverse events (AEs) and toxicities in the post-CAR T-cell therapy setting. First, Marion Subklewe, MD, Ludwig Maximilians University of Munich, Munich, Germany, outlines the m...

The evolving treatment landscape in MCL: chemo-free strategies, BTK inhibitors, and changing standards of care

April 16, 2026 7:20am 13 min

This VJHemOnc episode explores major shifts in frontline mantle cell lymphoma (MCL) care, highlighting the move from traditional chemotherapy to chemo‑free regimens and the growing role of BTK inhibitors. Michael Wang, M...

Advances in stem cell transplantation from EBMT 2026: managing GvHD, donor selection & evolving clinical strategies

April 09, 2026 11:42am 21 min

This episode reviews major advances presented at the EBMT 2026 meeting in Madrid, covering novel treatments for acute and chronic GVHD, including a promising microbiome-based therapy, and new targeted agents. Experts dis...

Myeloid Monthly: breaking news & updates from the classification advancement meeting

April 02, 2026 10:58am 35 min

This VJHemOnc podcast introduces the first edition of Myeloid Monthly, focusing on key developments in myeloid malignancies. Amer Zeidan, MD, Yale University, New Haven, CT, is joined by Robert Hasserjian, MD, Massachuse...

How AI is transforming hematologic oncology

March 27, 2026 7:03am 20 min

This VJHemOnc podcast explores how artificial intelligence (AI) is transforming hematologic oncology, from clinical research and diagnostics to risk prediction and therapy development. Aaron Gerds, MD, Cleveland Clinic, ...

MRD in ALL and AML: from prognostic marker to clinical endpoint

March 20, 2026 6:46am 21 min

This VJHemOnc podcast explores the evolving role of measurable residual disease (MRD) in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), from prognostic marker to clinical endpoint. Harry Erba, MD, P...

Nursing in CAR-T & cellular therapy: updates and insights from the EBMT-EHA CAR T-cell Meeting 2026

February 27, 2026 4:57am 17 min

Nurses play a key role in the CAR T-cell therapy process. In this podcast episode, you will hear insights into nursing in CAR-T and cellular therapy through exclusive interviews from the recent EBMT-EHA 8th European CAR ...

Recent BTK inhibitor trial updates across non-Hodgkin lymphoma subtypes

February 20, 2026 5:26am 26 min

Today’s episode of the VJHemOnc podcast features updates from a number of clinical trials exploring BTK inhibitors (BTKi) and BTKi-containing regimens in non-Hodgkin lymphoma (NHL) that were presented at the 2025 ASH Ann...

ASH 2025 highlights in AL amyloidosis: risk stratification, bispecific antibodies, CAR-T, & MRD

February 06, 2026 7:24am 28 min

This VJHemOnc podcast highlights key AL amyloidosis updates from ASH 2025, spanning risk stratification, optimisation of frontline therapy, emerging immunotherapies, and MRD assessment. Jahanzaib Khwaja, MD, FRCPath, Uni...

Top ASH 2025 updates in AML: redefining frontline therapy, menin inhibition, venetoclax-based triplets, & emerging immunotherapies

January 30, 2026 9:32am 18 min

This VJHemOnc podcast highlights key acute myeloid leukemia (AML) updates from ASH 2025, spanning frontline therapy, molecularly targeted approaches, venetoclax-based combinations, and emerging immunotherapies. Amir Fath...

Managing and preventing differentiation syndrome in APL

January 22, 2026 4:45am 13 min

In this episode of the VJHemOnc Podcast, we focus on the management and prevention of differentiation syndrome in acute promyelocytic leukemia (APL). We begin with a discussion with Yasmin Abaza, MD, Northwestern Univers...

Top ASH 2025 NHL updates: novel CAR T-cell therapies, fixed-duration strategies, evolving frontline approaches, & more

January 16, 2026 10:09am 42 min

This podcast highlights key non-Hodgkin lymphoma (NHL) updates from ASH 2025 across follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and Waldenström’s macroglobulinemia. John B...